Axa S.A. Cuts Position in Nyxoah S.A. (NASDAQ:NYXH)

Axa S.A. trimmed its position in shares of Nyxoah S.A. (NASDAQ:NYXH - Free Report) by 42.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 86,869 shares of the company's stock after selling 65,131 shares during the period. Axa S.A. owned approximately 0.26% of Nyxoah worth $695,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. LPL Financial LLC acquired a new position in Nyxoah during the 4th quarter worth about $102,000. Walleye Capital LLC lifted its position in shares of Nyxoah by 23.9% during the fourth quarter. Walleye Capital LLC now owns 14,831 shares of the company's stock worth $119,000 after purchasing an additional 2,862 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Nyxoah by 19.4% in the fourth quarter. Geode Capital Management LLC now owns 17,100 shares of the company's stock valued at $137,000 after purchasing an additional 2,774 shares during the period. Kovack Advisors Inc. grew its holdings in shares of Nyxoah by 100.0% in the fourth quarter. Kovack Advisors Inc. now owns 20,000 shares of the company's stock valued at $160,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in Nyxoah during the 4th quarter worth approximately $187,000.

Nyxoah Stock Performance

Shares of NYXH stock opened at $6.30 on Friday. Nyxoah S.A. has a 12 month low of $5.55 and a 12 month high of $12.21. The company has a current ratio of 5.28, a quick ratio of 4.95 and a debt-to-equity ratio of 0.21. The company has a market cap of $214.58 million, a P/E ratio of -3.37 and a beta of 1.56. The firm has a fifty day moving average price of $7.60 and a 200 day moving average price of $8.73.

Nyxoah (NASDAQ:NYXH - Get Free Report) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.03). The business had revenue of $1.35 million during the quarter, compared to analysts' expectations of $2.02 million. Nyxoah had a negative net margin of 1,043.93% and a negative return on equity of 51.68%. Sell-side analysts predict that Nyxoah S.A. will post -1.91 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Nyxoah in a research note on Tuesday, April 8th. Stifel Nicolaus lowered their target price on Nyxoah from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Monday, April 21st.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.

Want to see what other hedge funds are holding NYXH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nyxoah S.A. (NASDAQ:NYXH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.